

1 **A further investigation of the leishmaniosis outbreak in Madrid (Spain): low-**
2 **infectivity phenotype of the *Leishmania infantum* BOS1FL1 isolate to establish**
3 **infection in canine cells.**

4

5 Alicia Mas¹; Abel Martínez-Rodrigo¹; Jose Antonio Orden¹; Luis Miguel Viñals²;
6 Gustavo Domínguez-Bernal^{1*} and Javier Carrión¹

7

8 ¹ INMIVET, Department of Animal Health, School of Veterinary Medicine, Complutense
9 University of Madrid, 28040 Madrid, Spain

10 ² Centro de Transfusión Veterinario, Madrid, Spain

11 * Corresponding author. E-mail address: gdbernal@ucm.es

12 Telephone number: +34 913943712

13

14 **Abstract**

15 Human leishmaniosis caused by *Leishmania infantum* is a zoonotic disease, with dogs as
16 the main reservoir in Mediterranean Basin countries. The largest European outbreak of
17 human leishmaniosis declared in the southwestern Madrid region (Spain) is characterized
18 by unusual epidemiological and clinical features, such as the emergence of new wild
19 reservoirs (hares and rabbits), whereas the seroprevalence, infection, and severity of
20 canine leishmaniosis have not substantially changed since the first studies conducted in
21 Madrid before the outbreak. Previous studies reported that *L. infantum* isolates from the
22 Madrid leishmaniosis focus displayed elevated virulence in *in vivo* models of infection
23 and increased infectivity in murine target cells. With the aim of studying whether changes
24 in the host-parasite interaction and virulence profile have developed, we first assessed the
25 behaviour of one circulating isolate of the outbreak, IPER/ES/2012/BOS1FL1
26 (BOS1FL1), compared to that of a well-characterized strain from canine leishmaniosis,
27 MCAN/ES/1996/BCN150 (BCN150), in terms of infection capacity (percentage of
28 infected cells, representing infectivity, and number of amastigotes per infected cell,
29 representing the intensity of infection) in canine monocytes and macrophages. BCN150
30 displayed significantly higher infectivity (76.82 ± 4.40 vs 38.58 ± 2.19 ; $P < 0.0001$) and
31 intensity of infection (3.64 ± 0.13 vs 1.83 ± 0.12 ; $P < 0.0001$) than BOS1FL1 when
32 interacting with canine cells. Our ROS induction results did not differ significantly
33 between the two isolates or with the responses previously described for other *L. infantum*
34 isolates. Paradoxically, increased resilience to hydrogen peroxide exposure was observed
35 for BOS1FL1 (% viability 40.62 ± 5.54 vs 26.37 ± 2.93 ; $P = 0.039$). Finally, we
36 demonstrated that a decreased intracellular load of BOS1FL1 was associated with
37 increased IFN- γ (261.21 ± 26.29 vs 69.80 ± 9.02 ; $P = 0.0151$) and decreased IL-10
38 production (165.06 ± 23.87 vs 264.41 ± 30.58 ; $P = 0.0002$). In this study, we provide the

39 first detailed insight into the differences between the isolate BOS1FL1 from the outbreak
40 in Madrid and the well-characterized strain BCN150 MON-1 obtained from a dog in their
41 response to interacting with canine cells. However, further studies are necessary to shed
42 light on the immune mechanisms resulting in BOS1FL1 exhibiting less virulent behaviour
43 in canine cells than in cells derived from other host species.

44

45 **Key Words:** *Leishmania infantum*, ROS, Monocytes, Dogs, Virulence, Tropism

46

47 **1. Introduction**

48

49 Visceral leishmaniosis (VL) (Kassai et al., 1988) in the Mediterranean basin is a
50 protozoan zoonotic disease caused by *Leishmania infantum* and transmitted by
51 *Phlebotomus* species of sandfly vectors to humans and other mammals. Dogs are
52 considered the main domestic reservoir for *L. infantum* (Ashford, 1996). In Spain, canine
53 leishmaniosis (CanL) is endemic, and human leishmaniosis (HumL) has significantly
54 increased in incidence since 2009 due to the human leishmaniosis outbreak in the
55 southwestern region of Madrid (Spain). This outbreak is the largest outbreak in Europe
56 to date, with more than 700 cases (corresponding to a great increase in VL incidence
57 (35.9%), with 64.1 % increase in cutaneous leishmaniosis (CL) incidence). Remarkably,
58 70% of the patients are immunocompetent and atypical localized lymphadenopathic
59 leishmaniosis (LLL) has appeared in 19% of the VL cases (Arce et al., 2013; Horrillo et
60 al., 2015). Even though the dog is the main reservoir in the Mediterranean basin, disease
61 prevalence studies in dogs in the area did not reveal a significant increase in cases of
62 CanL (Miro et al., 2017). In this context, xenodiagnosis studies, based on the exposure of
63 infected lagomorphs to vector bites to assess their ability to transmit protozoa, have
64 shown lagomorph species (hares and rabbits) to play a role as sylvatic reservoirs (Jimenez
65 et al., 2014; Molina et al., 2012). Moreover, there are also molecular typing studies that
66 conclude that the human leishmaniosis outbreak of Madrid is not the responsibility of a
67 newly emerging genotype of *L. infantum*, since the parasitic isolates do not show
68 significant differences in their genotype from the strains circulating in a traditional way
69 in the cases of CanL in Madrid (Chicharro et al., 2013).

70

71 In the development of leishmaniasis, how the interaction between the parasite and the
72 host immune response occurs is fundamental to the establishment and subsequent
73 outcome of the disease (Scott and Novais, 2016). Immediately after infection, the innate
74 immune response is activated in the host and is characterized by the mobilization of
75 neutrophils and cells of the phagocytic mononuclear system (monocytes and
76 macrophages) (Hurrell et al., 2016; Moreira et al., 2016). The way in which this
77 interaction between monocytes and parasites occurs is critical to the susceptibility or
78 resistance outcome of infection. In this regard, host cells have mechanisms of defence
79 against infection, such as the development of the respiratory burst (RB) that is involved
80 in the production of compounds with leishmanicidal activity, such as nitric oxide (NO)
81 and reactive oxygen species (ROS) (Carneiro et al., 2016). NO production is dependent
82 on the expression of the enzyme nitric oxide synthetase resulting from the activation of
83 phagocytic cells by gamma-interferon (IFN- γ) during the development of a Th1-type
84 response. The production of ROS is a purely innate mechanism triggered by phagocytosis
85 of promastigotes. However, previous studies have shown that there are differences in the
86 ability of phagocytic cells to produce both compounds, depending on the species of origin
87 (Novais et al., 2014).

88

89 In a previous study, using an *ex vivo* murine model of VL, we revealed the high virulence
90 of the *L. infantum* isolate circulating in the outbreak, IPER/ES/2012/BOS1FL1
91 (BOS1FL1), compared with that of the strain MCAN/ES/1996/BCN150 (BCN150),
92 which was isolated from a dog (Fernandez-Cotrina et al., 2013). BOS1FL1 displays a
93 high intensity of infection and compromises the integrity of the immune defence
94 machinery of murine macrophages and dendritic cells (Dominguez-Bernal et al., 2014).
95 Furthermore, strong virulence of isolates circulating in the focus has been demonstrated

96 *in vivo* in BALB/c and hamster models of VL, which exhibit elevated parasite loads in
97 the spleen and liver accompanied by histological damage (Martin-Martin et al., 2015;
98 Mas et al., 2020). Indeed, high *L. infantum* loads in the vector *Phlebotomus perniciosus*
99 from the focus area have been found (Gonzalez et al., 2017). These facts support the
100 exceptional features of this outbreak. In the context of the unusual eco-epidemiological
101 properties of the leishmaniosis outbreak in Madrid, the aim of our study was to deepen
102 the knowledge of the diversity of pathogen host tropism. Thus, we compared the *ex vivo*
103 interactions of the *L. infantum* BOS1FL1 isolate with that of the BCN150 strain after
104 infection of canine monocytes (canMon) and macrophages (canM \emptyset).

105

106 **2. Materials and Methods**

107

108 **2.1. Ethics statement**

109 All the processes described in this manuscript complied with the Spanish (Law 63/2013)
110 and European Union legislation (2010/63/UE), and they were approved by the Ethics and
111 Welfare Committee for Animal Experimentation of Complutense University of Madrid
112 and Comunidad de Madrid authorities under procedural number PROEX 05/2018.

113

114 **2.2. Parasites**

115 The *L. infantum* IPER/ES/2012/BOS1FL1 (BOS1FL1) isolate was obtained from *P.*
116 *perniciosus* captured in the leishmaniosis outbreak in the southwestern region of Madrid
117 (Spain) (Martin-Martin et al., 2015), and it was compared to the well-characterized strain
118 named MCAN/ES/1996/BCN150, zymodeme MON-1 (BCN150), which has been used
119 previously in other studies related to canine visceral leishmaniosis (CanVL) (Fernandez-
120 Cotrina et al., 2013). With the purpose of minimizing potential changes in virulence due

121 to prolonged maintenance under *in vitro* conditions, both *L. infantum* strains were
122 passaged through BALB/c mice ($n = 1$ mouse/isolate) as described previously
123 (Dominguez-Bernal et al., 2015). For re-isolation, two months after infection, spleens
124 were homogenized and cultivated in NNN medium at 26 °C for 4-7 days until
125 promastigotes expanded (passage number 1). Then, they were grown in Schneider's
126 medium (Dominique Dutscher, Issy-les-Moulineaux, France) supplemented with 20%
127 heat-inactivated foetal bovine serum (FBS, Gibco, Life Technologies, Thermo Fisher
128 Scientific, Waltham, MA, USA) and a mixture of antibiotics (200 U/mL penicillin, 200
129 µg/mL streptomycin) (Lonza, Basel, Switzerland), and they were maintained at 26 °C
130 until the infection assays. Similar passages between isolates were compared, and no
131 passage greater than 8/10 was employed for the studies.

132

133 **2.3. *In vitro* growth kinetics and metacyclogenesis**

134 Promastigotes of both isolates were centrifuged and resuspended in 4 mL of complete
135 Schneider's medium with a final concentration of 5×10^5 parasites/mL. They were
136 incubated at 26 °C for 20 days without adding fresh medium until the concentration was
137 below the initial concentration. Parasite densities were obtained by daily counting of
138 viable promastigotes using a Neubauer chamber (Brand). Promastigote morphology was
139 evaluated microscopically. The promastigote flagellum/cell body length ratio was
140 determined as a measure for metacyclogenesis as described elsewhere (Ouakad et al.,
141 2011). Parasites were considered metacyclic when presenting a ratio >2 .

142

143 **2.4. Hydrogen peroxide stress assay**

144 To assess the inhibitory effect of reactive oxygen species on parasite growth, 10^7
145 promastigotes/mL stationary phase *L. infantum* BCN150 and BOS1FL1 were incubated

146 in a 96-well flat-bottomed plate in complete Schneider's medium supplemented with
147 hydrogen peroxide (H₂O₂, Panreac, Castellar del Vallés, Spain) in increasing
148 concentrations (0-10 mM). After 2 h at 26 °C, MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-
149 diphenyl-2H-tetrazolium bromide, Molecular Probes by Life Technologies] solution (5
150 mg/mL) was added and incubated at 37 °C for 1 h. Dimethyl sulfoxide (DMSO, Sigma-
151 Aldrich, St. Louis, MO, USA) was used to dissolve the formazan crystals. Optical density
152 was measured in a spectrophotometer at 570-660 nm. TritonTM X-100 (2%) (Sigma-
153 Aldrich) was used as a negative control.

154

155 **2.5. Isolation of canMon and canMø from peripheral blood**

156 Healthy canine donors ($n = 10$) of different breeds, middle age and both sexes that
157 complied with the criteria of being negative for *Leishmania* by serology and PCR were
158 employed. A total of 250 mL of whole peripheral blood was collected via jugular
159 venepuncture from each dog in citrate-phosphate-dextrose-adenine (CPDA)
160 anticoagulant. Peripheral blood mononuclear cells (PBMCs) were isolated through
161 density gradient centrifugation (Histopaque-1077, Sigma-Aldrich) as previously
162 described (Araujo et al., 2011; Martínez-Rodrigo et al., 2019). Monocytes were obtained
163 by magnetic separation using mouse anti-human CD14-coupled microbeads (Miltenyi
164 Biotec Ltd., USA) according to the manufacturer's instructions and maintained in
165 complete medium (CM) consisting of RPMI-1640 medium with 2 mM L-glutamine (GE
166 Healthcare, Spain) supplemented with 10% FBS, a mixture of antibiotics (100 U/mL
167 penicillin, 100 µg/mL streptomycin) (Lonza) and 10 mM HEPES (Lonza) at 37 °C until
168 infection. CD14-negative cells were collected and frozen in CM containing 40% FBS and
169 10% dimethyl sulfoxide (DMSO) and stored at -80 °C until the infection assay was
170 performed. For macrophage differentiation, CD14-positive monocytes (6×10^6 cells per

171 mL) were seeded in 25 cm² flasks and differentiated into canMø by the addition of 33
172 ng/mL recombinant human Granulocyte Macrophage Colony-Stimulating Factor (GM-
173 CSF, Kingfisher Biotech, Saint Paul, MN) for a period of 7 days at 37 °C and 5% CO₂.
174 At day 3, the medium was replaced with medium containing the same concentration of
175 freshly added growth factor. To determine the phenotype of canMon and canMø, both
176 cells were double stained on days 0 and 7 with αCD14 (mouse anti-human CD14:RPE,
177 TÜK4, Bio-Rad, Madrid, Spain) in combination with αMHC-II (rat anti-dog MHC class
178 II, YKIX334.2, Bio-Rad) and αCD86 (mouse anti-human CD86:RPE, BU63, Bio-Rad)
179 in combination with αCD40 (mouse anti-human CD40:FITC, LOB7/6, Bio-Rad).
180 CanMon were characterized on day 0 as CD14⁺ MHC class II⁺, CD40^{+/-} and CD86⁻
181 cells, while canMø were immunophenotyped on day 7 as CD14^{+/-} MHC class II ^{+/-},
182 CD40⁺ and CD86⁻ cells. CD14-negative cells were stained with αCD3 (rat anti-canine
183 CD3, CA17.2A12, Bio-Rad) to characterize them as T lymphocytes (CD14-CD3⁺).
184 Fluorescence intensities were quantified using a FACScan flow cytometer (BD
185 Biosciences, CAI, UCM, Madrid, Spain), and data were processed with FlowJo X
186 software version 10.0.7 (Beckton Dickinson, Franklin lakes, NJ, USA).

187

188 **2.6. *L. infantum* ex vivo infection assays**

189 Cells (canMon or canMø) were seeded at a concentration of 5x10⁵ cells on poly-L-lysine
190 (Sigma Aldrich)-coated 13 mm diameter coverslips into P24 cell culture plates to improve
191 cell adherence. After 12 h, cells were infected with stationary phase *L. infantum*
192 promastigotes at a ratio of 5:1 (parasites:cells) at 37 °C in 5% CO₂ for 4 h. Subsequently,
193 extracellular parasites were removed by washing the cells, and they were incubated with
194 autologous lymphocytes as a co-culture (5:1 ratio lymphocytes:monocytes/macrophages)
195 in complete medium for an additional 24 and 72 h (Almeida et al., 2017). To determine

196 the antileishmanial activity of canMon and canMø, 400 cells were counted in duplicate
197 after Giemsa staining under an Olympus BX41 optical microscope. The percentage of
198 infected cells (referred to as infectivity) and the mean number of amastigotes per infected
199 cell (referred to as intensity of infection) were evaluated. Infection index was calculated
200 by multiplication of both parameters as previously described (Dominguez-Bernal et al.,
201 2014).

202

203 **2.7. Development of the oxidative burst**

204 NO production was evaluated indirectly by assessing the nitrite concentration using the
205 Griess reagent. Cells (canMon and canMø) were infected with *L. infantum* at a ratio of
206 5:1 parasites:cells for 24 and 72 h. After 4 h of infection, extracellular promastigotes were
207 removed by washing, and cells were stimulated with lipopolysaccharide (LPS) (1 µg/mL,
208 Sigma-Aldrich) (Ding et al., 1988; Dominguez-Bernal et al., 2012). ROS levels were
209 determined by flow cytometry using DHE (Dihydroethidium, Sigma-Aldrich). When
210 required, cells were pre-treated with PMA (Phorbol 12-myristate 13-acetate, Sigma-
211 Aldrich) at 1 µg/mL as an ROS inducer (Ponath and Kaina, 2017). Infected cells were
212 incubated with 10 mM DHE for 30 minutes at 37 °C in a CO₂ incubator. PMA (1 µg/mL,
213 Sigma-Aldrich)-treated cells were used as a positive control (Wang et al., 2013).

214

215 **2.8. Quantification of cytokine, TLR-2, TLR-4, arginase and nitric oxide mRNA** 216 **expression levels**

217 Total RNA for cytokine expression analysis was extracted from the abovementioned
218 infected canMon- and canMø by an NZY Total RNA Isolation Kit (NZYTech, Lisbon,
219 Portugal) following the manufacturer's instructions. Reverse transcription was carried out
220 using an NZY First-Strand cDNA Synthesis Kit (NZYTech, Lisbon, Portugal). Between

221 200 and 400 ng of total RNA was analysed in each sample. Primers used for canine
222 Arginase, NO synthetase, Toll-like receptors (TLR-2 and TLR-4), IL-1 β , IL-6, IL-10, IL-
223 12p40, IL-18, TNF- α , and the housekeeping genes β -actin and GAPDH were designed in
224 this study and are listed in supplementary Table S1. Real-time PCRs were performed in
225 20 μ L using NZYSpeedy qPCR Green Master Mix (2x) (NZYTech, Lisbon, Portugal), 5
226 pmol of each primer and 4 μ L of diluted cDNA samples in a 7500 FAST Real-Time PCR
227 System (Applied Biosystems, Foster City, CA, USA). The relative quantification of
228 cytokine mRNA expression levels (fold change in expression) was carried out by the
229 comparative $2^{-\Delta\Delta C_t}$ method (Schmittgen and Livak, 2008).

230

231 **2.9. Quantification of cytokine production and arginase activity in the co-culture** 232 **system**

233 Cells (canMon and canM \emptyset) were cultured overnight in P24 tissue culture-treated plates.
234 To determine cytokine production (TNF- α , IFN- γ and IL-10), canMon/canM \emptyset were
235 infected with *L. infantum* and co-cultured with autologous lymphocytes as described
236 previously. Culture supernatants were collected after 72 h, and cytokines were determined
237 by ELISA according to the manufacturer's instructions (Duoset ELISA Development
238 System Kits R&D Systems, Minneapolis, MN, USA). The intracellular arginase activity
239 from infected cells was measured as previously described (Dominguez-Bernal et al.,
240 2015) after incubating for 30 min in lysis buffer (0.1 M Tris-HCl, pH 7.5, 300 μ M NaCl,
241 1 μ M PMSF, 1% Triton X-100). One unit of enzyme activity was defined as the amount
242 of enzyme catalysing the formation of 1 mMol of urea/min.

243

244 **2.10. Statistical Analysis**

245 Data sets were analysed as the mean \pm standard error of the mean (SEM). The significance
246 of the growth curve and MTT assay results was calculated using a parametric statistical
247 test: Student's *t* test for pairwise comparisons. For the evaluation of ROS production, *ex*
248 *vivo* infection assays and qPCR results, a parametric statistical test was used: one-way
249 ANOVA followed by Tukey's test for multiple comparisons. The arginase activity, NO
250 production and cytokine production (measured by ELISA) were analysed by two-way
251 ANOVA followed by Tukey's test for multiple comparisons. All analyses were
252 performed using GraphPad Prism software (version 6.0 for Windows, San Diego, CA,
253 USA). Significant differences were determined and are designated with asterisks, as
254 follows: **P* < 0.05, ***P* < 0.01.

255

256 **3. Results**

257

258 **3.1. *In vitro* characterization of *L. infantum* isolates**

259 With the aim of ruling out that any different putative *in vivo* behaviour between the isolate
260 BOS1FL1 and the reference strain (BCN150) was associated with a modification in
261 growth features, we analysed the *in vitro* growth kinetics of promastigotes from both
262 isolates over 20 days in culture medium. BCN150 and BOS1FL1 did not differ in their
263 speed of growth to reach the stationary phase or the highest density of viable parasites at
264 the same time between the 5th and 8th days (Fig. 1A). The development of metacyclic
265 forms also followed similar dynamics (Fig. 1B). No obvious differences were observed,
266 implying that any difference in the behaviour between BCN150 and BOS1FL1 could not
267 be attributed to a difference in their growth capability or *in vitro* metacyclogenesis. In
268 addition, to extend the analysis to the differential susceptibility, if any, to the inhibitory
269 effect of ROS depending on the isolate, the parasites were exposed to exogenous

270 hydrogen peroxide (H₂O₂) stress. The results showed a reduction in the viability (%) of
271 promastigotes in both isolates in a dose-dependent manner (Fig. 2); however, the viability
272 of BCN150 was slightly lower than that of BOS1FL1, a difference that was statistically
273 significant at 4 mM ($P \leq 0.01$). Thus, BOS1FL1 was slightly less susceptible than
274 BCN150 to the effect of ROS *in vitro*, which suggests the potential for a specific selective
275 advantage when faced with host-derived oxidative radicals.

276

277 **3.2. Differential interaction of *L. infantum* isolates with canine macrophages and** 278 **monocytes**

279 In this study, we first proposed to investigate whether there are any differences in the
280 behaviour of BCN150 and BOS1FL1 in their interaction with canM ϕ . We infected canM ϕ
281 with promastigotes of both isolates and followed the progression of infection for 72 h.
282 BCN150 had a significantly greater infection index than BOS1FL1 at 24 h (279 ± 18 vs
283 73 ± 7 ; $P < 0.0001$) and 72 h (176 ± 17 vs 53 ± 3 ; $P = 0.0002$). These differences
284 corresponded with an increased percentage of infected cells by BCN150 and the greatest
285 intensity of infection over 24 and 72 h (Fig. 3A, B).

286

287 A similar trend was observed with canMon, with a significantly higher infection index
288 for BCN150 than for BOS1FL1 at 24 h (200 ± 28 vs 86 ± 6 ; $P = 0.0002$) and 72 h ($435 \pm$
289 16 vs 142 ± 14 ; $P < 0.0001$). According to these results, BCN150 showed the most
290 effective infection capacity in canine macrophages and monocytes, obtaining both a
291 higher percentage and intensity of infection at the two temporal points (Fig. 3A, B).

292

293 **3.3. Characterization of the oxidative burst after *L. infantum* infection in canine** 294 **macrophages and monocytes**

295 To assess whether there was a difference in the induction of NO after infection with *L.*
296 *infantum*, we measured the nitrite levels in canine monocytes and macrophages. However,
297 we could not detect any production in either non-infected cells or cells infected with any
298 of the *L. infantum* isolates/strains. To investigate whether ROS play any role in parasite
299 killing in canine monocytes, we assessed ROS production after infection with both
300 *L. infantum*. The highest production of ROS was obtained in canMon 24 h after infection
301 with BCN150 (mean \pm SEM: 295.2 \pm 7.2). This production was even higher than the levels
302 resulting from the specific induction of ROS by treatment with PMA. In canM ϕ , there
303 was also an enhanced ROS production in response to infection, although it was not greater
304 than the levels induced by the PMA control (Fig. 4). To further investigate whether ROS
305 production could be related to the different intracellular behaviours displayed by BCN150
306 and BOS1FL1, we performed infections of canMon and canM ϕ treated with PMA before
307 infection. In canine monocytes after 24 h and 72 h, the percentage of infected cells, as
308 well as the overall burden of intracellular parasites, was significantly reduced in the PMA-
309 treated cells (Fig. 5A, B). According to that result, the infection index was significantly
310 reduced compared to that with non-treated cells (Table 1). Furthermore, the PMA
311 reduction effect was higher in the case of BCN150 (Table 1). In canine macrophages, the
312 percentage of infection was only significantly reduced at 24 h after infection, and the
313 parasite load was not only not reduced but also even increased at 72 h in treated cells
314 infected with BOS1FL1 (Fig. 5A, B).

315

316 **3.4. Modulation of arginase activity and nitric oxide production in canine** 317 **monocytes and macrophages**

318 To further investigate whether BOS1FL1 or BCN150 could subvert host cell responses
319 that kill intracellular parasites in different ways, we compared the arginase activity levels

320 in *ex vivo* infected canMon and canMø in co-culture with autologous lymphocytes at 72
321 h after infection. Unfortunately, as described above for NO production, it was not possible
322 to detect arginase enzyme activity that exceeded the detection limits of the technique in
323 canMon and canMø infected with BOS1FL1 and BCN150. To assess whether the
324 negative results were due to the sensitivity of the method or because the levels were
325 completely undetectable, we evaluated arginase (*Arg2*) and inducible nitric oxide
326 synthase (iNOS) expression after infection of cells followed by analysis of their mRNA
327 expression by qRT-PCR. We could not find a significant level of iNOS expression. In
328 addition, although we found a low expression level of arginase 2 (*Arg2*), it did not differ
329 between cells infected with any isolate and non-infected cells (data not shown).

330

331 **3.5. mRNA expression pattern of TLR-2, TLR-4 and cytokines**

332 We investigated whether the differences in isolate-specific intracellular behaviour would
333 also impact cytokine levels. Thus, we examined the expression of pro-inflammatory (IL-
334 1 β , IL-6, IL-12p40, IL-18, and TNF- α) and anti-inflammatory (IL-10) cytokines in canine
335 monocytes and macrophages following infection with BCN150 and BOS1FL1. Our
336 results showed upregulation of IL-1 β and TNF- α production in the infected monocytes
337 compared to uninfected cells. These expression levels were even higher in the case of
338 BCN150, although the differences were not significantly different from those observed
339 with BOS1FL1 (Fig. 6A, B). The expression levels of the other important pro-
340 inflammatory cytokines associated with *L. infantum* infection analysed, such as IL-18,
341 IL-12p40, and IL-6, were only slightly expressed in canine monocytes after parasite
342 infection, with no significant differences between infected cells and non-infected control
343 cells.

344

345 Among anti-inflammatory cytokines, we found upregulation of IL-10 in BCN150-
346 infected monocytes with respect to uninfected and BOS1FL1-infected cells (Fig. 6C).
347 Infected macrophages presented very low expression of every cytokine analysed, with no
348 significant differences between the isolates or compared with the control cells.

349

350 TLR expression has been associated with leishmanial infection, and we evaluated *ex vivo*
351 expression of TLR-2 and TLR-4 after canine monocyte and macrophage infection. Our
352 results revealed a significant increase in the expression of TLR-2 and TLR-4 in infected
353 monocytes compared to that in uninfected cells. This upregulation was higher in the case
354 of BCN150 infection than BOS1FL1 infection, although the differences were not
355 statistically significant (Fig. 6D). Finally, there were no significant differences in TLR-2
356 and TLR-4 expression after infection with any of the isolates compared to those in the
357 control group macrophages (Fig. 6D).

358

359 **3.6. IL-10, TNF- α , and INF- γ production by lymphocytes in co-culture with** 360 ***L. infantum*-infected canMon and canM ϕ**

361 As a next step, we investigated the balance in the synthesis of anti-inflammatory and pro-
362 inflammatory cytokines resulting from the co-culture of canMon/canM ϕ after infection
363 with parasites. Infection with BCN150 and BOS1FL1 significantly increased pro-
364 inflammatory cytokine (TNF- α , and especially IFN- γ) and anti-inflammatory cytokine
365 (IL-10) expressions to levels even higher than those observed with control LPS treatment
366 (Fig. 7). There were no significant differences in TNF- α production between both isolates.
367 However, in both cell types, BCN150 induced significantly higher IL-10 (264 ± 31 vs 165
368 ± 24 pg/mL; $P = 0.0002$) and lower IFN- γ (196 ± 3 vs 261 ± 26 pg/mL; $P = 0.0151$)
369 production than did BOS1FL1. Taken together, these results indicate that BCN150

370 enhances the anti-inflammatory/pro-inflammatory cytokine secretion rate, thus
371 suggesting a switch to the susceptibility Th2 profile in those cells infected with BCN150.

372

373 **4. Discussion**

374

375 The establishment and outcome of leishmaniosis is intrinsically associated with the
376 balance between the immune response of the host and the parasite's ability to survive.
377 Numerous mechanisms developed by the pathogen are known to modify its virulence,
378 allowing it to evade both innate and adaptive immune responses, which may be implicated
379 in its adaptation to new hosts and the spread of the disease (Gupta et al., 2013). When *L.*
380 *infantum* infection begins, monocytes are one of the first immune host cells to interact
381 with the parasite, and the way in which this interaction occurs could determine infection
382 control or progression (Viana et al., 2013).

383

384 In this study, we speculated whether a change in the host tropism between isolates of
385 *L. infantum* could be responsible for the special features in terms of virulence, outcome
386 and host scope of leishmaniosis in the outbreak of Madrid (Horrillo et al., 2019; Miro et
387 al., 2017). To assess this hypothesis, we compared the behaviour of one isolate
388 (BOS1FL1) and one strain (BCN150) of *L. infantum* during interactions with monocytes
389 and macrophages of canine origin.

390

391 Phenotypic characterization of promastigotes *in vitro* can be relevant to identifying any
392 effects, of growth kinetics or metacyclogenesis, on infection ability other than host
393 interaction. No obvious differences were observed in the *in vitro* growth dynamics or the
394 development of metacyclic forms of BCN150 and BOS1FL1. Furthermore, when

395 comparing the percentage and intensity of infection obtained when infecting macrophages
396 and monocytes of canine origin, we observed a clear difference between them. BCN150
397 had a higher infection index than BOS1FL1. Interestingly, these results were opposite to
398 those previously described for both isolates in macrophages and dendritic cells of murine
399 origin (Dominguez-Bernal et al., 2014).

400

401 To understand the reasons behind the distinctive differences in intracellular behaviour
402 between BOS1FL1 and BCN150, we first investigated whether they exerted detrimental
403 effects on leishmanicidal host machinery. Thus, we compared the levels of NO and
404 arginase activity in *ex vivo* infected canMon and canMø at 96 h post-infection. We found
405 undetectable NO and arginase production in BOS1FL1- and BCN150-infected canMon
406 and canMø in the presence of LPS. These results were also obtained when mRNA
407 expression of *arg2* and *iNOS* levels were assessed. In both cases, the expression was
408 negligible in infected cells with either isolate and in non-infected cells, as previously
409 described (Singh et al., 2018). While there are studies demonstrating that *Leishmania*
410 killing in murine macrophages is directly related to the activity of NO (Mauel et al.,
411 1991), this fact does not appear to play a significant role in the defence of human
412 monocytes or macrophages, (Almeida et al., 2017; Gantt et al., 2001) being replaced by
413 the synthesis of reactive oxygen species (ROS) (Novais et al., 2014).

414

415 Furthermore, different expression levels of NO and arginase in rodent macrophages
416 determine the resistance (for rats) and susceptibility (for mice) to *Toxoplasma gondii*
417 infection, indicating that those mechanisms could be involved in variation in
418 susceptibility and host tropism (Li et al., 2012). In dogs, the information is much more
419 limited, and the role, if any, of NO production in macrophages is controversial since some

420 authors reported the production of NO (de Almeida et al., 2017; Petitdidier et al., 2016),
421 while others, in agreement with our results, showed undetectable levels of NO production
422 for canMon and canMø infected with *L. infantum* (Martínez-Rodrigo et al., 2019;
423 Montserrat-Sangrà et al., 2018; Turchetti et al., 2015). Our data demonstrate that NO and
424 arginase do not play a role in controlling parasites *in vitro* in canMon and canMø, neither
425 determining the difference observed between the isolates.

426

427 However, high ROS production was induced in canMon and canMø after infection.
428 Although there were no significant differences between BCN150 and BOS1FL1, the
429 induction of ROS production highlights the important defensive role of these compounds
430 in the innate responses of canine cells to leishmaniosis, substantiating the hypothesis that
431 the defensive role of the canine monocyte oxidative burst is dependent on ROS and not
432 on NO production.

433

434 The role of ROS is relevant for the destruction of a variety of intracellular pathogens,
435 such as *Leishmania*; therefore, the viability of *Leishmania* in the presence of H₂O₂ has
436 been previously analysed (Cortes et al., 2018). More interestingly, there have been
437 reported differences in ROS susceptibility between natural hybrids of *L. infantum* and *L.*
438 *major* (Cortes et al., 2018). Here, we described a higher resilience to different H₂O₂
439 concentrations in BOS150 than in BCN1FL1, suggesting the potential for a specific
440 advantage to resistance to the host oxidative radicals or to those immune cells with higher
441 oxidative radical production. Interestingly, after induction of ROS production with PMA,
442 there was a clear increase in killing activity, with reductions both the percentage of
443 infection and the intensity of infection, although this effect was less intense for BOS1FL1,
444 which is more resistant to exogenous hydrogen peroxide (H₂O₂) (Fig. 2). Whether this

445 difference in resistance could be related to a specific selective advantage against
446 differential host-derived oxidative radicals that led to tropism adaptation and difference
447 virulence behaviour needs to be further studied.

448

449 Given that ROS susceptibility data indicated a BCN150/BOS1FL1-specific impact on the
450 innate immune response orchestrated by canMon and canMø, we assessed whether these
451 differences also affect the adaptive immune response. Thus, we next examined the
452 involvement of relevant pro-inflammatory (IL-1 β , IL-6, IL-12, IL-18, and TNF- α) and
453 anti-inflammatory (IL-10) cytokines that could explain the differences in the behaviour
454 of the isolates after infection of canMon or canMø. We observed that BCN150 and
455 BOS1FL1 did not induce detectable expression levels of IL-6, IL-12 and IL-18. Similarly,
456 the absence of IL-12 in supernatants of virulent or avirulent *L. major*-infected human
457 macrophages has been reported (Brodszyn et al., 2000). Moreover, strains of *L. major*
458 with different virulence in BALB/c mice and *L. infantum* with viscerotropic and
459 dermatropic tropism displayed similar cytokine-inducing capacities in human monocytes
460 (Meddeb-Garnaoui et al., 2009). Together with our results, these data suggest that the
461 virulence of *Leishmania* does not influence the inhibition of IL-12 production by canine
462 monocytes or macrophages.

463

464 On the other hand, we detected increased expression of IL-1 β and TNF- α in infected
465 monocytes; however, although slightly higher expression was displayed in BCN150-
466 infected cells, it was not significantly different between the two isolates. *Leishmania* are
467 poor inducers of IL-1 β alone but do promote IL-1 β production when macrophages are
468 also stimulated with LPS (Scott and Novais, 2016). We found increased IL-1 β expression
469 levels in monocytes infected with *Leishmania* without stimulation with LPS. IL-1 β can

470 also enhance inflammation by promoting TNF- α expression, as we observed in
471 monocytes infected with both *Leishmania* isolates. Similar to TNF- α , IL-1 β can play a
472 dual role, leading to protective or pathogenic effects during *Leishmania* infection (Scott
473 and Novais, 2016). Only a few studies have investigated the role of IL-1 β in *Leishmania*-
474 infected patients, and these studies have indicated that IL-1 β also contributes to disease
475 in humans (Santos et al., 2018). Unfortunately, no data are described involving IL-1 β with
476 the exacerbation of canine leishmaniosis. Whether this upregulation in canMon is related
477 to an increase in the severity associated with inflammasome activation must be
478 deciphered in future studies. Finally, IL-10 expression was significantly higher in
479 BCN150-infected canMon than in BOS1FL1-infected canMon. Although some studies
480 have suggested that this cytokine is not associated with disease susceptibility in dogs
481 (Solano-Gallego et al., 2016), many others (de Almeida et al., 2017; Martínez-Rodrigo,
482 2019 #3167; Martínez-Rodrigo et al., 2019; Medina-Colorado et al., 2017; Reza et al.,
483 2019) are in agreement with our data, where a reduction in the infection index is
484 associated with a decrease in IL-10 expression in canine monocytes. These results were
485 also obtained in the supernatant of infected monocytes and macrophages subsequently
486 co-cultured with autologous lymphocytes, where higher production of IL-10 along with
487 lower INF- γ compatible with a susceptible infectivity phenotype was shown by BCN150,
488 while BOS1FL1 displayed a more resistant profile characterized by lower IL-10 together
489 with higher INF- γ values.

490

491 TLRs expressed on innate immune cells are critical for *Leishmania* recognition, which
492 determines the outcome of the infection (Faria et al., 2012). Although most studies
493 appoint a protective role for TLRs, there is growing evidence that in some cases, TLRs
494 facilitate infection (Faria et al., 2012). However, although a higher infection index of

495 BCN150 was positively associated with increased expression of TLR-4 compared to that
496 of BOS1FL1, this difference was not statistically significant.

497

498 While most previous studies focused on the requirement of TLRs for cytokine synthesis
499 and for the development of adaptive immunity, studies on how those receptors contribute
500 to the control of parasite intracellular growth are still largely absent (Faria et al., 2012).

501 In this study, we could not associate a significant role in the upregulation of TLRs with
502 the different intracellular behaviours of BCN150 and BOS1FL1. Furthermore, several
503 studies have shown a role for TLRs in the generation of ROS during *Leishmania* infection
504 (Srivastava et al., 2012). Therefore, increased ROS production in canine infected cells
505 could be due to increased expression of TLRs in monocytes differentially driven by
506 BOS1FL1 or BCN150; however, we did not find any association between upregulation
507 of TLR-4 and the slight increase in ROS production with BCN150.

508

509 The immune response triggered by infection of canine monocytes with one isolate from
510 the human leishmaniosis outbreak did not differ significantly from the traditional
511 response described in canine target cells by traditional isolates (Gradoni, 2015; Reis et
512 al., 2010). The results obtained from the cytokine, TLR, and oxidative burst profiles do
513 not seem to account for the reduced infection index observed in BOS1FL1 infected cells
514 and therefore do not explain the changes observed in terms of epidemiology, pathology
515 and host-tropism preference described in the outbreak in Madrid. The virulence factors
516 involved in the differential outcome of infection with different *L. infantum* strains are still
517 poorly defined.

518

519 **5. Conclusions**

520

521 These findings provide insights to improve the understanding of the mechanisms used by
522 *L. infantum* to subvert canine mammalian cell defence tools. Furthermore, the differences
523 in cytokine profiles and ROS susceptibility between isolates indicate that these
524 mechanisms may also account for variation in susceptibility of individuals within the
525 natural population of *L. infantum*. Nevertheless, the different behaviour described for
526 *L. infantum* isolates according to the mammal origin of the host cells must be related to
527 factors beyond the different expression levels of iNOS, Arg2 and TLR profiles. Therefore,
528 further studies analysing new virulence factors and pathogenic mechanisms for host and
529 tropism adaptation are necessary to elucidate how isolates modify their virulence and
530 finetune their adaptation to new ecological niches, vectors and host and tissue tropism.

531

532 **Funding sources**

533 Funding: This research was partially supported by grants from the UCM-Santander
534 (Grant PR75/18-21558) and from the Comunidad de Madrid (Spain) PLATESA2-CM
535 (S2018/BAA-4370). Alicia Mas (AM) and Abel Martínez-Rodrigo (AMR) were
536 supported by a fellowship from the Complutense University of Madrid-Santander.

537

538 **Disclosure statement**

539 The authors declare that they have no competing interests.

540

541 **Author contributions**

542 Conceptualization, AM, GDB and JC; methodology, AM and AMR; formal analysis, AM
543 and AMR; resources, LMV and JAO; writing—original draft preparation, AM and GDB;

544 writing—review and editing, AMR and JAO; supervision, GDB and JC.; funding
545 acquisition, GDB and JC.

546

547 **Acknowledgements**

548 We are grateful to Miguel Rodríguez Castaño[†] (Departamento de Medicina y Cirugía
549 Animal-Hospital Clínico Veterinario Complutense, Facultad de Veterinaria, UCM,
550 Madrid) for generously providing the blood from healthy dogs. We also acknowledge
551 Maribel Jiménez and Ricardo Molina (ISCIH) for the kind gift of the isolate BOS1FL1.

552

553 **References**

554

- 555 Almeida, B.F.M., Silva, K.L.O., Venturin, G.L., Chiku, V.M., Leal, A.A.C., Bosco, A.M.,
556 Ciarlini, P.C., Lima, V.M.F., 2017. Induction of haem oxygenase-1 increases
557 infection of dog macrophages by *L. infantum*. *Parasite Immunol.*
- 558 Araujo, M.S., de Andrade, R.A., Sathler-Avelar, R., Magalhaes, C.P., Carvalho, A.T.,
559 Andrade, M.C., Campolina, S.S., Mello, M.N., Vianna, L.R., Mayrink, W., Reis,
560 A.B., Malaquias, L.C., Rocha, L.M., Martins-Filho, O.A., 2011. Immunological
561 changes in canine peripheral blood leukocytes triggered by immunization with
562 first or second generation vaccines against canine visceral leishmaniasis. *Vet*
563 *Immunol Immunopathol* 141, 64-75.
- 564 Arce, A., Estirado, A., Ordobas, M., Sevilla, S., Garcia, N., Moratilla, L., de la Fuente,
565 S., Martinez, A.M., Perez, A.M., Aranguéz, E., Iriso, A., Sevillano, O., Bernal, J.,
566 Vilas, F., 2013. Re-emergence of leishmaniasis in Spain: community outbreak in
567 Madrid, Spain, 2009 to 2012. *Euro Surveill* 18, 20546.
- 568 Ashford, R.W., 1996. Leishmaniasis reservoirs and their significance in control. *Clin*
569 *Dermatol* 14, 523-532.
- 570 Brodskyn, C., Beverley, S.M., Titus, R.G., 2000. Virulent or avirulent (dhfr-ts-)
571 *Leishmania major* elicit predominantly a type-1 cytokine response by human cells
572 in vitro. *Clinical and experimental immunology* 119, 299-304.
- 573 Carneiro, P.P., Conceicao, J., Macedo, M., Magalhaes, V., Carvalho, E.M., Bacellar, O.,
574 2016. The Role of Nitric Oxide and Reactive Oxygen Species in the Killing of
575 *Leishmania braziliensis* by Monocytes from Patients with Cutaneous
576 *Leishmaniasis*. *PLoS One* 11, e0148084.
- 577 Chicharro, C., Llanes-Acevedo, I.P., Garcia, E., Nieto, J., Moreno, J., Cruz, I., 2013.
578 Molecular typing of *Leishmania infantum* isolates from a leishmaniasis outbreak
579 in Madrid, Spain, 2009 to 2012. *Euro Surveill* 18, 20545.
- 580 Cortes, S., Albuquerque-Wendt, A., Maia, C., Carvalho, M., Lima, I.A., de Freitas,
581 L.A.R., Dos-Santos, W.L.C., Campino, L., 2018. Elucidating in vitro and in vivo
582 phenotypic behaviour of *L. infantum*/*L. major* natural hybrids. *Parasitology*, 1-8.

583 de Almeida, B.F.M., Silva, K.L.O., Venturin, G.L., Chiku, V.M., Leal, A.A.C., Bosco,
584 A.M., Ciarlini, P.C., de Lima, V.M.F., 2017. Induction of heme oxygenase-1
585 increases infection of dog macrophages by *L. infantum*. *Parasite Immunol.*
586 Ding, A.H., Nathan, C.F., Stuehr, D.J., 1988. Release of reactive nitrogen intermediates
587 and reactive oxygen intermediates from mouse peritoneal macrophages.
588 Comparison of activating cytokines and evidence for independent production. *J*
589 *Immunol* 141, 2407-2412.

590 Dominguez-Bernal, G., Horcajo, P., Orden, J.A., De La Fuente, R., Herrero-Gil, A.,
591 Ordonez-Gutierrez, L., Carrion, J., 2012. Mitigating an undesirable immune
592 response of inherent susceptibility to cutaneous leishmaniasis in a mouse model:
593 the role of the pathoantigenic HISA70 DNA vaccine. *Vet Res* 43, 59.

594 Dominguez-Bernal, G., Horcajo, P., Orden, J.A., Ruiz-Santa-Quiteria, J.A., De La
595 Fuente, R., Ordonez-Gutierrez, L., Martinez-Rodrigo, A., Mas, A., Carrion, J.,
596 2015. HisAK70: progress towards a vaccine against different forms of
597 leishmaniasis. *Parasites & vectors* 8, 629.

598 Dominguez-Bernal, G., Jimenez, M., Molina, R., Ordonez-Gutierrez, L., Martinez-
599 Rodrigo, A., Mas, A., Cutuli, M.T., Carrion, J., 2014. Characterisation of the ex
600 vivo virulence of *Leishmania infantum* isolates from *Phlebotomus perniciosus*
601 from an outbreak of human leishmaniasis in Madrid, Spain. *Parasites & vectors*
602 7, 499.

603 Faria, M.S., Reis, F.C., Lima, A.P., 2012. Toll-like receptors in leishmania infections:
604 guardians or promoters? *J Parasitol Res* 2012, 930257.

605 Fernandez-Cotrina, J., Iniesta, V., Belinchon-Lorenzo, S., Munoz-Madrid, R., Serrano,
606 F., Parejo, J.C., Gomez-Gordo, L., Soto, M., Alonso, C., Gomez-Nieto, L.C.,
607 2013. Experimental model for reproduction of canine visceral leishmaniasis by
608 *Leishmania infantum*. *Veterinary parasitology* 192, 118-128.

609 Gantt, K.R., Goldman, T.L., McCormick, M.L., Miller, M.A., Jeronimo, S.M.,
610 Nascimento, E.T., Britigan, B.E., Wilson, M.E., 2001. Oxidative responses of
611 human and murine macrophages during phagocytosis of *Leishmania chagasi*. *J*
612 *Immunol* 167, 893-901.

613 Gonzalez, E., Alvarez, A., Ruiz, S., Molina, R., Jimenez, M., 2017. Detection of high
614 *Leishmania infantum* loads in *Phlebotomus perniciosus* captured in the
615 leishmaniasis focus of southwestern Madrid region (Spain) by real time PCR.
616 *Acta tropica* 171, 68-73.

617 Gradoni, L., 2015. Canine *Leishmania* vaccines: Still a long way to go. *Veterinary*
618 *parasitology* 208, 94-100.

619 Gupta, G., Oghumu, S., Satoskar, A.R., 2013. Mechanisms of immune evasion in
620 leishmaniasis. *Adv Appl Microbiol* 82, 155-184.

621 Horrillo, L., Castro, A., Matia, B., Molina, L., Garcia-Martinez, J., Jaqueti, J., Garcia-
622 Arata, I., Carrillo, E., Moreno, J., Ruiz-Giardin, J.M., San Martin, J., 2019.
623 Clinical aspects of visceral leishmaniasis caused by *L. infantum* in adults. Ten
624 years of experience of the largest outbreak in Europe: what have we learned?
625 *Parasites & vectors* 12, 359.

626 Horrillo, L., San Martin, J.V., Molina, L., Madronal, E., Matia, B., Castro, A., Garcia-
627 Martinez, J., Barrios, A., Cabello, N., Arata, I.G., Casas, J.M., Ruiz Giardin, J.M.,
628 2015. Atypical presentation in adults in the largest community outbreak of
629 leishmaniasis in Europe (Fuenlabrada, Spain). *Clin Microbiol Infect* 21, 269-273.

630 Hurrell, B.P., Regli, I.B., Tacchini-Cottier, F., 2016. Different *Leishmania* Species Drive
631 Distinct Neutrophil Functions. *Trends Parasitol* 32, 392-401.

- 632 Jimenez, M., Gonzalez, E., Martin-Martin, I., Hernandez, S., Molina, R., 2014. Could
633 wild rabbits (*Oryctolagus cuniculus*) be reservoirs for *Leishmania infantum* in the
634 focus of Madrid, Spain? *Veterinary parasitology* 202, 296-300.
- 635 Kassai, T., Cordero del Campillo, M., Euzeby, J., Gaafar, S., Hiepe, T., Himonas, C.A.,
636 1988. Standardized nomenclature of animal parasitic diseases (SNOAPAD).
637 *Veterinary parasitology* 29, 299-326.
- 638 Li, Z., Zhao, Z.J., Zhu, X.Q., Ren, Q.S., Nie, F.F., Gao, J.M., Gao, X.J., Yang, T.B., Zhou,
639 W.L., Shen, J.L., Wang, Y., Lu, F.L., Chen, X.G., Hide, G., Ayala, F.J., Lun, Z.R.,
640 2012. Differences in iNOS and arginase expression and activity in the
641 macrophages of rats are responsible for the resistance against *T. gondii* infection.
642 *PLoS One* 7, e35834.
- 643 Martin-Martin, I., Jimenez, M., Gonzalez, E., Eguiluz, C., Molina, R., 2015. Natural
644 transmission of *Leishmania infantum* through experimentally infected
645 *Phlebotomus perniciosus* highlights the virulence of *Leishmania* parasites
646 circulating in the human visceral leishmaniasis outbreak in Madrid, Spain. *Vet*
647 *Res* 46, 138.
- 648 Martínez-Rodrigo, A., Mas, A., Fernández-Cotrina, J., Belinchón-Lorenzo, S., Orden,
649 J.A., Arias, P., de la Fuente, R., Carrión, J., Domínguez-Bernal, G., 2019. Strength
650 and medium-term impact of HisAK70 immunization in dogs: Vaccine safety and
651 biomarkers of effectiveness for ex vivo *Leishmania infantum* infection.
652 *Comparative Immunology, Microbiology and Infectious Diseases*.
- 653 Mas, A., Martínez-Rodrigo, A., Orden, J.A., Molina, R., Jiménez, M., Jiménez, M.,
654 Carrión, J., Domínguez-Bernal, G., 2020. Properties of virulence emergence of
655 *Leishmania infantum* isolates from *Phlebotomus perniciosus* collected during the
656 human leishmaniasis outbreak in Madrid, Spain. Hepatic histopathology and
657 immunological parameters as virulence markers in the mouse model. *Transbound*
658 *Emerg Dis*.
- 659 Mael, J., Corradin, S.B., Buchmuller Rouiller, Y., 1991. Nitrogen and oxygen
660 metabolites and the killing of *Leishmania* by activated murine macrophages. *Res*
661 *Immunol* 142, 577-580; discussion 593-574.
- 662 Meddeb-Garnaoui, A., Zrelli, H., Dellagi, K., 2009. Effects of tropism and virulence of
663 *Leishmania* parasites on cytokine production by infected human monocytes.
664 *Clinical and experimental immunology* 155, 199-206.
- 665 Medina-Colorado, A.A., Osorio, E.Y., Saldarriaga, O.A., Travi, B.L., Kong, F., Spratt,
666 H., Soong, L., Melby, P.C., 2017. Splenic CD4+ T Cells in Progressive Visceral
667 Leishmaniasis Show a Mixed Effector-Regulatory Phenotype and Impair
668 Macrophage Effector Function through Inhibitory Receptor Expression. *PLoS*
669 *One* 12, e0169496.
- 670 Miro, G., Muller, A., Montoya, A., Checa, R., Marino, V., Marino, E., Fuster, F.,
671 Escacena, C., Descalzo, M.A., Galvez, R., 2017. Epidemiological role of dogs
672 since the human leishmaniasis outbreak in Madrid. *Parasites & vectors* 10, 209.
- 673 Molina, R., Jimenez, M.I., Cruz, I., Iriso, A., Martin-Martin, I., Sevillano, O., Melero, S.,
674 Bernal, J., 2012. The hare (*Lepus granatensis*) as potential sylvatic reservoir of
675 *Leishmania infantum* in Spain. *Veterinary Parasitology* 190, 268-271.
- 676 Montserrat-Sangrà, S., Ordeix, L., Martínez-Orellana, P., Solano-Gallego, L., 2018.
677 Parasite Specific Antibody Levels, Interferon- γ and TLR2 and TLR4 Transcripts
678 in Blood from Dogs with Different Clinical Stages of Leishmaniasis. *Vet Sci* 5,
679 31.

- 680 Moreira, P.R., Fernando, F.S., Montassier, H.J., Andre, M.R., de Oliveira Vasconcelos,
681 R., 2016. Polarized M2 macrophages in dogs with visceral leishmaniasis. *Vet*
682 *Parasitol* 226, 69-73.
- 683 Novais, F.O., Nguyen, B.T., Beiting, D.P., Carvalho, L.P., Glennie, N.D., Passos, S.,
684 Carvalho, E.M., Scott, P., 2014. Human classical monocytes control the
685 intracellular stage of *Leishmania braziliensis* by reactive oxygen species. *The*
686 *Journal of infectious diseases* 209, 1288-1296.
- 687 Ouakad, M., Vanaerschot, M., Rijal, S., Sundar, S., Speybroeck, N., Kestens, L., Boel,
688 L., De Doncker, S., Maes, I., Decuypere, S., Dujardin, J.C., 2011. Increased
689 metacyclogenesis of antimony-resistant *Leishmania donovani* clinical lines.
690 *Parasitology* 138, 1392-1399.
- 691 Petitdidier, E., Pagniez, J., Papierok, G., Vincendeau, P., Lemesre, J.L., Bras-Goncalves,
692 R., 2016. Recombinant Forms of *Leishmania amazonensis* Excreted/Secreted
693 Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in
694 Dogs. *PLoS neglected tropical diseases* 10, e0004614.
- 695 Ponath, V., Kaina, B., 2017. Death of Monocytes through Oxidative Burst of
696 Macrophages and Neutrophils: Killing in Trans. *PLoS One* 12, e0170347.
- 697 Reis, A.B., Giunchetti, R.C., Carrillo, E., Martins-Filho, O.A., Moreno, J., 2010.
698 Immunity to *Leishmania* and the rational search for vaccines against canine
699 leishmaniasis. *Trends Parasitol* 26, 341-349.
- 700 Reza, S., Hasan, N.A., Maryam, N.F., Fahimeh, B., Ghahremani, A., GholamReza, H.,
701 Amin, G.M., 2019. Cytokine profile and nitric oxide levels in macrophages
702 exposed to *Leishmania infantum* FML. *Experimental parasitology* 203, 1-7.
- 703 Santos, D., Campos, T.M., Saldanha, M., Oliveira, S.C., Nascimento, M., Zamboni, D.S.,
704 Machado, P.R., Arruda, S., Scott, P., Carvalho, E.M., Carvalho, L.P., 2018. IL-
705 1beta Production by Intermediate Monocytes Is Associated with
706 Immunopathology in Cutaneous Leishmaniasis. *The Journal of investigative*
707 *dermatology* 138, 1107-1115.
- 708 Scott, P., Novais, F.O., 2016. Cutaneous leishmaniasis: immune responses in protection
709 and pathogenesis. *Nature reviews. Immunology* 16, 581-592.
- 710 Singh, N., Kumar, R., Chauhan, S.B., Engwerda, C., Sundar, S., 2018. Peripheral Blood
711 Monocytes With an Antiinflammatory Phenotype Display Limited Phagocytosis
712 and Oxidative Burst in Patients With Visceral Leishmaniasis. *The Journal of*
713 *infectious diseases* 218, 1130-1141.
- 714 Solano-Gallego, L., Montserrat-Sangra, S., Ordeix, L., Martinez-Orellana, P., 2016.
715 *Leishmania infantum*-specific production of IFN-gamma and IL-10 in stimulated
716 blood from dogs with clinical leishmaniosis. *Parasites & vectors* 9, 317.
- 717 Srivastava, A., Singh, N., Mishra, M., Kumar, V., Gour, J.K., Bajpai, S., Singh, S.,
718 Pandey, H.P., Singh, R.K., 2012. Identification of TLR inducing Th1-responsive
719 *Leishmania donovani* amastigote-specific antigens. *Molecular and cellular*
720 *biochemistry* 359, 359-368.
- 721 Turchetti, A.P., da Costa, L.F., Romao Ede, L., Fujiwara, R.T., da Paixao, T.A., Santos,
722 R.L., 2015. Transcription of innate immunity genes and cytokine secretion by
723 canine macrophages resistant or susceptible to intracellular survival of
724 *Leishmania infantum*. *Vet Immunol Immunopathol* 163, 67-76.
- 725 Viana, K.F., Aguiar-Soares, R.D., Roatt, B.M., Resende, L.A., da Silveira-Lemos, D.,
726 Correa-Oliveira, R., Martins-Filho, O.A., Moura, S.L., Zanini, M.S., Araujo,
727 M.S., Reis, A.B., Giunchetti, R.C., 2013. Analysis using canine peripheral blood
728 for establishing in vitro conditions for monocyte differentiation into macrophages

729 for *Leishmania chagasi* infection and T-cell subset purification. *Veterinary*
730 *parasitology* 198, 62-71.
731 Wang, X., Fang, H., Huang, Z., Shang, W., Hou, T., Cheng, A., Cheng, H., 2013. Imaging
732 ROS signaling in cells and animals. *J Mol Med (Berl)* 91, 917-927.
733
734

736 **Table 1. Effect of PMA treatment on the infection index in canine monocytes and**
 737 **macrophages.**

738

Infection index	canMon				canMø			
	BCN150		BOS1FL1		BCN150		BOS1FL1	
	Untreated cells	PMA	Untreated cells	PMA	Untreated cells	PMA	Untreated cells	PMA
24h after infection	286 ± 15	18 ± 2**	152 ± 13	26 ± 1**	449 ± 3	328 ± 10	332 ± 11	288 ± 17
72h after infection	298 ± 34	42 ± 4**	161 ± 12	37 ± 9**	414 ± 4	432 ± 38	330 ± 20	500 ± 30**

739

740 CanMon and CanMø were pre-treated with PMA at 1 µg/mL over 30 min and infected
 741 with *L. infantum* BCN150 or BOS1FL1 at a ratio of 5:1 parasites:cells. Statistical analysis
 742 was performed with one-way ANOVA followed by Tukey's test for multiple
 743 comparisons. Asterisks (*) indicate statistically significant differences (* $P < 0.05$, ** $P <$
 744 0.01).

745

746 **Supplementary Table 1 (S1). List of sequences of primers used for cytokine real-**
747 **time PCR (qPCR) and standard curve data.**

Target	Primer	Sequence (5' → 3')	Orientation	Position	Product (bp)	NCBI ^a Accession number	Reference
<i>β-actin</i>	qmB-actin-1D	GGCACCACACCTTCTACAATG	Forward	343-363	151	NM_001195845.2	This work
	qmB-actin-1R	TGGATGGCTACGTACATGGCT	Reverse	476-496			
GAPDH	qGAPDH-1D	CCAGAACATCATCCCTGC	Forward	603-620	240	AB038240.1	This work
	qGAPDH-1R	GAGACCACCTGGTCCTCAGTG	Reverse	822-842			
IL-1β	qIL-1 β-1D	GATGGCTTACTCCAGTAACAATG	Forward	1429-1451	158	XM_005630074.2	This work
	qIL-1 β-1R	GCCTCAGACTCTTGTTACAGAGC	Reverse	1564-1586			
IL-6	qIL-6-1D	GAGACCTGCTTGACAAGAATCAC	Forward	367-389	123	NM_001003301.1	This work
	qIL-6-1R	GATCTTGGTACTCATGTGCACAG	Reverse	467-489			
IL-10	qIL-10-1D	CACGACCCAGACATCAAGAACCAC	Forward	304-327	142	EU426968.1	This work
	qIL-10-1R	TACTAAATGCGCTCTTCACCTGC	Reverse	423-445			
IL-12	qIL-12-1D	AGCAGTGACACTTTCAGCAGAG	Forward	513-534	143	NM_001003292.1	This work
	qIL-12-1R	GCTTGTGAATAGCATCCACCACG	Reverse	633-655			
IL-18	qIL-18-1D	GATTCTGACTGTACAGATAATGC	Forward	211-233	99	NM_001003169.1	This work
	qIL-18-1R	CTTCACAGAGATAGTTACTGCCAG	Reverse	286-309			
TNF-α	qTNFa-1D	AGCCAGTAGCTCATGTTGTAGC	Forward	260-281	122	NM_001003244.4	This work
	qTNFa-1R	CGGCACTATCAGCTGGTTGTCTG	Reverse	359-381			
Arginase	qArg-1D	GCATGGCTATTGGAAGCATCTC	Forward	794-815	182	XM_532053.6	This work
	qArg-1R	GAATCCTGGTACATCGGGTATC	Reverse	954-975			
iNOS	qInos-1D	GTCTTGTCTGGGAGCCATCATG	Forward	586-607	161	XM_022422531.1	This work
	qInos-1R	CCACCCTGGCCAGATGTTCCCTC	Reverse	725-746			
TLR2	qTLR 2-1D	GAACTTATCCGACACAAGAATGC	Forward	1331-1353	164	EU487534.1	This work
	qTLR 2-1R	AGGCATCTGGTAGAGTCTTCAAC	Reverse	1472-1494			
TLR4	qTLR 4-1D	ATTCCAGTTTGAAGCAGGCCAGTG	Forward	1300-1323	134	NM_001002950.2	This work
	qTLR 4-1R	GACTTCGAGGCTGACCAAGCCATC	Reverse	1410-1433			

748

749 ^aNCBI accession numbers are for cDNA sequences used in primer design

750 (<https://www.ncbi.nlm.nih.gov/nucleotide>).

751

752 **Figure captions**

753

754 **Figure 1. Growth dynamics (A) and *in vitro* metacyclogenesis development (B) of the**
755 ***Leishmania infantum* isolates BCN150 and BOS1FL1.** Promastigotes of each isolate
756 were counted using a Neubauer chamber and a 1/100 dilution. Parasites were considered
757 metacyclic when presenting a flagellum/cell body length ratio >2 . The results are
758 represented by the mean values and standard errors of the mean of two replicates from
759 three independent assays. Statistical analysis was performed with Student's *t* test.
760 Asterisks (*) indicate statistically significant differences ($*P < 0.05$, $**P < 0.01$).

761

762 **Figure 2. Parasite viability (%) of the BCN150 and BOS1FL1 isolates exposed to**
763 **H₂O₂.** Promastigotes of the *L. infantum* isolates BCN150 and BOS1FL1 were exposed to
764 an increasing concentration of H₂O₂. The viability percentage shown was obtained from
765 one representative of four independent experiments with four replicates each. Statistical
766 analysis was performed with Student's *t* test. Asterisks (*) indicate statistically significant
767 differences ($*P < 0.05$, $**P < 0.01$).

768

769 **Figure 3. Percentage of infection and intensity of infection in canine monocytes and**
770 **macrophages.** canMon and canM ϕ were infected with *L. infantum* BCN150 or BOS1FL1
771 at a ratio of 5:1 parasites:cells. Data from one representative of four independent
772 experiments are shown. The percentage of infected cells (A) and the mean number of
773 amastigotes per infected cell (B) were evaluated. Statistical analysis was performed with
774 one-way ANOVA followed by Tukey's test for multiple comparisons. Asterisks (*)
775 indicate statistically significant differences ($*P < 0.05$, $**P < 0.01$).

776

777 **Figure 4. ROS generation by canine monocytes and macrophages after infection**
778 **with *L. infantum*.** canMon (A) and canM ϕ (B) were infected with *L. infantum* BCN150
779 or BOS1FL1 at a ratio of 5:1 parasites:cells. After 24 h or 72 h of infection, cells were
780 treated with DHE (10 μ M) for 30 minutes. PMA (1 μ g/mL) was used as a positive control.
781 The results are represented by the mean fluorescence intensity (MFI) of two replicates
782 from one assay representative of three independent experiments collected using flow
783 cytometry and analysed using FlowJo software. Statistical analysis was performed with
784 one-way ANOVA followed by Tukey's test for multiple comparisons. Asterisks (*)
785 indicate statistically significant differences (* P < 0.05, ** P < 0.01).

786

787 **Figure 5. Effect of PMA treatment on the percentage of infection and intensity of**
788 **infection in canine monocytes and macrophages.** canMon and canM ϕ were pre-treated
789 with PMA at 1 μ g/mL over 30 min and infected with *L. infantum* BCN150 or BOS1FL1
790 at a ratio of 5:1 parasites:cells. Data from one representative of four independent
791 experiments are shown. The percentage of infected cells (A) and the mean number of
792 amastigotes per infected cell (B) were evaluated. Statistical analysis was performed with
793 one-way ANOVA followed by Tukey's test for multiple comparisons. Asterisks (*)
794 indicate statistically significant differences (* P < 0.05, ** P < 0.01) between the untreated
795 and PMA-treated groups.

796

797 **Figure 6. mRNA expression of anti-inflammatory (IL-10) or proinflammatory (IL-**
798 **1 β , TNF- α) cytokines and TLR-2 and TLR-4 in canine monocytes and macrophages.**
799 Graphs represent the relative quantification by the comparative $2^{-\Delta\Delta C_t}$ method of IL-1 β
800 (A), TNF- α (B), IL-10 (C), and TLR-2 and TLR-4 (D) mRNA expression levels (fold
801 change in expression) in canMon and canM ϕ challenged for 72 h with *L. infantum*

802 BCN150 or BOS1FL1 (at a ratio of 5:1) in relation to those in non-infected cells. The
803 results show the mean of four independent experiments. Statistical analysis was
804 performed with one-way ANOVA followed by Tukey's test for multiple comparisons.
805 Asterisks (*) indicate statistically significant differences (* $P < 0.05$, ** $P < 0.01$).

806

807 **Figure 7. IL-10, TNF- α , and INF- γ production by lymphocytes in co-culture with**
808 ***L. infantum*-infected canine monocytes and macrophages.** The graph represents the
809 concentration of cytokines in supernatants obtained from lymphocytes in co-culture with
810 non-infected cells or canine monocytes (**A**) or macrophages (**B**) challenged with
811 *L. infantum* BCN150 or BOS1FL1. Each column and error bar represent the mean and
812 SEM of three replicates from three independent experiments. Statistical analysis was
813 performed with two-way ANOVA followed by Tukey's test for multiple comparisons.
814 Asterisks (*) indicate statistically significant differences (* $P < 0.05$, ** $P < 0.01$).